Technical Analysis for VEGPF - Vectura Group Plc

Grade Last Price % Change Price Change
grade F 0.795 -24.87% -0.2631
VEGPF closed down 24.87 percent on Wednesday, March 18, 2020, on 0 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical VEGPF trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
New 52 Week Closing Low Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Older signals for VEGPF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Medicine Health Clinical Medicine Pharmaceutical Products European Union Asthma Dosage Forms Chronic Obstructive Pulmonary Disease Respiratory Therapy Pulmonary Arterial Hypertension Chronic Lower Respiratory Diseases Combination Drugs Treatment Of Asthma And Chronic Obstructive Pulmonary Disease Clinical Stage Product Copd Clinical Stage Products Dry Powder Inhaler Ellipta Fluticasone Furoate/Vilanterol

Is VEGPF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 2.51
52 Week Low 0.795
Average Volume 67,027
200-Day Moving Average 0.0000
50-Day Moving Average 1.0008
20-Day Moving Average 0.9919
10-Day Moving Average 0.9871
Average True Range 0.0587
ADX 10.3
+DI 35.3931
-DI 62.5472
Chandelier Exit (Long, 3 ATRs ) 0.9139
Chandelier Exit (Short, 3 ATRs ) 0.9711
Upper Bollinger Band 1.1186
Lower Bollinger Band 0.8652
Percent B (%b) -0.28
BandWidth 25.5469
MACD Line -0.0109
MACD Signal Line -0.0047
MACD Histogram -0.0062
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.7950
Resistance 3 (R3) 0.7950 0.7950 0.7950
Resistance 2 (R2) 0.7950 0.7950 0.7950 0.7950
Resistance 1 (R1) 0.7950 0.7950 0.7950 0.7950 0.7950
Pivot Point 0.7950 0.7950 0.7950 0.7950 0.7950
Support 1 (S1) 0.7950 0.7950 0.7950 0.7950 0.7950
Support 2 (S2) 0.7950 0.7950 0.7950 0.7950
Support 3 (S3) 0.7950 0.7950 0.7950
Support 4 (S4) 0.7950